ProCE Banner Series

Partners in Patient Care: Nursing Considerations in the Management of CLL/SLL

Interact with an expert during a 1-hour CE-certified live meeting examining recent advances and nursing best practices in the management of patients with CLL. Register today!

  ANCC
Who Should Attend

This program is intended for hematology/oncology nurses and other HCPs who care for patients with CLL/SLL.

All Events

Past Events

November

04

2023

Partners in Patient Care: Nursing Considerations in the Management of CLL/SLL

12:00 PM - 1:00 PM Pacific Time (PT)

In-person

Private Event | Host Group AZ, Tuscon, Arizona

December

12

2023

Partners in Patient Care: Nursing Considerations in the Management of CLL/SLL

2:30 PM - 3:30 PM Eastern Time (ET)

In-person

Private Event | Host Group in GA, Savannah, Georgia

January

16

2024

Partners in Patient Care: Nursing Considerations in the Management of CLL/SLL [Open Registration]

6:30 PM - 7:30 PM Central Time (CT)

In-person

Private Event | Host Group in KSC, Kansas City, Missouri

January

17

2024

Partners in Patient Care: Nursing Considerations in the Management of CLL/SLL

6:30 PM - 7:30 PM Eastern Time (ET)

In-person

Private Event | Host Group in PA, Ambler, Pennsylvania

January

18

2024

Partners in Patient Care: Nursing Considerations in the Management of CLL/SLL [Open Registration]

6:15 PM - 7:15 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group OH, Cleveland, Ohio

January

24

2024

Partners in Patient Care: Nursing Considerations in the Management of CLL/SLL

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event | Host Group in NY, New York City, New York

January

31

2024

Partners in Patient Care: Nursing Considerations in the Management of CLL/SLL

6:00 PM - 7:00 PM Central Time (CT)

In-person

Private Event | Host Group in AL, Birmingham, Alabama

February

15

2024

Partners in Patient Care: Nursing Considerations in the Management of CLL/SLL [Open Registration]

6:30 PM - 7:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group GA, Lawrenceville, Georgia

Faculty

ProCE Banner Faculty
Nichole Fisher, RN, BSN

Supervisor, Clinical Research
Willamette Valley Cancer Institute & Research Center
Eugene, Oregon 

ProCE Banner Faculty
Amy Goodrich, RN, MSN, CRNP-AC

Research Associate/Nurse Practitioner
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

ProCE Banner Faculty
Josie Montegaard, MSN, AGPCNP-BC

Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Topics

  • Contemporary treatment of CLL: MoA and efficacy/safety of BTK inhibitors and BCL-2 inhibitors
  • Dosing
  • Adverse event management
  • Supportive care advice
  • Counseling patients on drug–drug interactions and drug adherence
  • Key variables in deciding between regimens
  • Engaging patients in shared decision-making
  • Cultivating shared understanding/treatment goals with patients
  • On the horizon: novel BTK inhibitors, BTK plus BCL-2 inhibitor combinations, CAR T-cell therapy
  • Audience question and answer session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Chronic Lymphocytic Leukemia (CLL)

Target Audience
This program is intended for hematology/oncology nurses and other HCPs who care for patients with CLL/SLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify critical molecular pathways involved in the pathogenesis of CLL/SLL and differences in efficacy and safety profiles of the agents targeting these pathways
  • Implement evidenced-based interventions to optimize outcomes for patients with CLL/SLL, including managing AEs, addressing medication adherence, and minimizing potential drug–drug interactions
  • Employ available resources to effectively engage patients in shared decision-making, cultivating a shared understanding of treatment goals and the risks and benefits of various CLL/SLL treatment options, considering the agent’s toxicity profile, prognostic variables, and patient’s comorbidities

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca Pharmaceuticals and Lilly.